Literature DB >> 28375571

HLA Mismatching Favoring Host-Versus-Graft NK Cell Activity Via KIR3DL1 Is Associated With Improved Outcomes Following Lung Transplantation.

J R Greenland1,2, H Sun3, D Calabrese2, T Chong2, J P Singer2, J Kukreja4, S R Hays2, J A Golden2,4, G H Caughey1,2,5, J M Venstrom2, R Rajalingam3.   

Abstract

Chronic lung allograft dysfunction (CLAD) is linked to rejection and limits survival following lung transplantation. HLA-Bw4 recipients of HLA-Bw6 grafts have enhanced host-versus-graft (HVG) natural killer (NK) cell activity mediated by killer cell immunoglobulin-like receptor (KIR)3DL1 ligand. Because NK cells may promote tolerance by depleting antigen-presenting cells, we hypothesized improved outcomes for HLA-Bw4 recipients of HLA-Bw6 grafts. We evaluated differences in acute cellular rejection and CLAD-free survival across 252 KIR3DL1+ recipients from University of California, San Francisco (UCSF). For validation, we assessed survival and freedom from bronchiolitis obliterans syndrome (BOS), retransplantation, or death in 12 845 non-KIR typed recipients from the United Network for Organ Sharing (UNOS) registry. Cox proportional hazards models were adjusted for age, gender, ethnicity, transplant type, and HLA mismatching. HVG-capable subjects in the UCSF cohort had a decreased risk of CLAD or death (hazard ratio [HR] 0.57, 95% confidence interval [CI] 0.36-0.88) and decreased early lymphocytic bronchitis. The HVG effect was not significant in subjects with genotypes predicting low KIR3DL1 expression. In the UNOS cohort, HVG-capable subjects had a decreased risk of BOS, retransplant, or death (HR 0.95, 95% CI 0.91-0.99). Survival improved with the higher-affinity Bw4-80I ligand and in Bw4 homozygotes. Improved outcomes in HVG-capable recipients are consistent with a protective NK cell role. Augmentation of NK activity could supplement current immunosuppression techniques.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  immunobiology; lung (allograft) function/dysfunction; lung transplantation/pulmonology; major histocompatibility complex (MHC); natural killer (NK) cells/NK receptors; translational research/science

Mesh:

Substances:

Year:  2017        PMID: 28375571      PMCID: PMC5519429          DOI: 10.1111/ajt.14295

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  22 in total

1.  Licensing of natural killer cells by host major histocompatibility complex class I molecules.

Authors:  Sungjin Kim; Jennifer Poursine-Laurent; Steven M Truscott; Lonnie Lybarger; Yun-Jeong Song; Liping Yang; Anthony R French; John B Sunwoo; Suzanne Lemieux; Ted H Hansen; Wayne M Yokoyama
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

2.  Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism.

Authors:  C M Gardiner; L A Guethlein; H G Shilling; M Pando; W H Carr; R Rajalingam; C Vilches; P Parham
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

3.  Association of large-airway lymphocytic bronchitis with bronchiolitis obliterans syndrome.

Authors:  John R Greenland; Kirk D Jones; Steve R Hays; Jeffrey A Golden; Anatoly Urisman; Nicholas P Jewell; George H Caughey; Neil N Trivedi
Journal:  Am J Respir Crit Care Med       Date:  2012-12-13       Impact factor: 21.405

4.  Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin.

Authors:  Chien-Hsing Chang; Puja Sapra; Sailaja S Vanama; Hans J Hansen; Ivan D Horak; David M Goldenberg
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

5.  'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection.

Authors:  Mark T Orr; William J Murphy; Lewis L Lanier
Journal:  Nat Immunol       Date:  2010-02-28       Impact factor: 25.606

6.  Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS.

Authors:  Maureen P Martin; Xiaojiang Gao; Jeong-Hee Lee; George W Nelson; Roger Detels; James J Goedert; Susan Buchbinder; Keith Hoots; David Vlahov; John Trowsdale; Michael Wilson; Stephen J O'Brien; Mary Carrington
Journal:  Nat Genet       Date:  2002-07-22       Impact factor: 38.330

Review 7.  Variable interactions of recipient killer cell immunoglobulin-like receptors with self and allogenic human leukocyte antigen class I ligands may influence the outcome of solid organ transplants.

Authors:  Raja Rajalingam
Journal:  Curr Opin Organ Transplant       Date:  2008-08       Impact factor: 2.640

8.  Bronchoalveolar lavage cell immunophenotyping facilitates diagnosis of lung allograft rejection.

Authors:  J R Greenland; N P Jewell; M Gottschall; N N Trivedi; J Kukreja; S R Hays; J P Singer; J A Golden; G H Caughey
Journal:  Am J Transplant       Date:  2014-02-11       Impact factor: 8.086

Review 9.  Natural killer cells in infection and inflammation of the lung.

Authors:  Fiona J Culley
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

10.  Natural Killer Cell Receptor NKG2A/HLA-E Interaction Dependent Differential Thymopoiesis of Hematopoietic Progenitor Cells Influences the Outcome of HIV Infection.

Authors:  Edmond J Yunis; Viviana Romero; Felipe Diaz-Giffero; Joaquin Zuñiga; Prasad Koka
Journal:  J Stem Cells       Date:  2007
View more
  8 in total

1.  Dectin-1 genetic deficiency predicts chronic lung allograft dysfunction and death.

Authors:  Daniel R Calabrese; Ping Wang; Tiffany Chong; Jonathan Hoover; Jonathan P Singer; Dara Torgerson; Steven R Hays; Jeffrey A Golden; Jasleen Kukreja; Daniel Dugger; Jason D Christie; John R Greenland
Journal:  JCI Insight       Date:  2019-11-14

2.  The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial.

Authors:  Efthymia Iliana Matthaiou; Husham Sharifi; Christian O'Donnell; Wayland Chiu; Clark Owyang; Paulami Chatterjee; Ihsan Turk; Laura Johnston; Theresa Brondstetter; Karen Morris; Guang-Shing Cheng; Joe L Hsu
Journal:  Bone Marrow Transplant       Date:  2022-05-31       Impact factor: 5.174

Review 3.  Natural killer cells in lung transplantation.

Authors:  Daniel R Calabrese; Lewis L Lanier; John R Greenland
Journal:  Thorax       Date:  2018-10-31       Impact factor: 9.139

4.  Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury.

Authors:  Daniel R Calabrese; Emily Aminian; Benat Mallavia; Fengchun Liu; Simon J Cleary; Oscar A Aguilar; Ping Wang; Jonathan P Singer; Steven R Hays; Jeffrey A Golden; Jasleen Kukreja; Daniel Dugger; Mary Nakamura; Lewis L Lanier; Mark R Looney; John R Greenland
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

Review 5.  Genome-Wide Study Updates in the International Genetics and Translational Research in Transplantation Network (iGeneTRAiN).

Authors:  Claire E Fishman; Maede Mohebnasab; Jessica van Setten; Francesca Zanoni; Chen Wang; Silvia Deaglio; Antonio Amoroso; Lauren Callans; Teun van Gelder; Sangho Lee; Krzysztof Kiryluk; Matthew B Lanktree; Brendan J Keating
Journal:  Front Genet       Date:  2019-11-15       Impact factor: 4.599

6.  Allele imputation for the killer cell immunoglobulin-like receptor KIR3DL1/S1.

Authors:  Genelle F Harrison; Laura Ann Leaton; Erica A Harrison; Katherine M Kichula; Marte K Viken; Jonathan Shortt; Christopher R Gignoux; Benedicte A Lie; Damjan Vukcevic; Stephen Leslie; Paul J Norman
Journal:  PLoS Comput Biol       Date:  2022-02-22       Impact factor: 4.475

Review 7.  Lymphocytic Airway Inflammation in Lung Allografts.

Authors:  Jesse Santos; Daniel R Calabrese; John R Greenland
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

8.  Screening and identification of key regulatory connections and immune cell infiltration characteristics for lung transplant rejection using mucosal biopsies.

Authors:  Meng-Xi Xiu; Zu-Ting Liu; Jian Tang
Journal:  Int Immunopharmacol       Date:  2020-08-10       Impact factor: 4.932

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.